BI 425809 dose 2

DRUG2 trials

Sponsors

Boehringer Ingelheim

Conditions

Alzheimer DiseaseSchizophrenia

Phase 2

BI 425809 in Patients With Cognitive Impairment Due to Alzheimer's Disease.

CompletedNCT02788513

Boehringer IngelheimAlzheimer Disease

Start: 2016-08-11End: 2019-10-11Updated: 2020-11-06

Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schizophrenia

CompletedNCT02832037

Boehringer IngelheimSchizophrenia

Start: 2016-07-25End: 2020-01-29Updated: 2021-02-24

Related Papers

The Phase III CONNEX programme assessing the efficacy and safety of iclepertin in patients with schizophrenia: Trial design and recruitment update

European Psychiatry2024-04-011 citations

Efficacy and Safety of Iclepertin (BI 425809) in Patients With Schizophrenia: CONNEX, A Phase III Randomized Controlled Trial Program

CNS Spectrums2023-04-012 citations

Efficacy and safety of the novel GlyT1 inhibitor BI 425809 in Alzheimer’s dementia: a randomized controlled trial

Alzheimer s Research & Therapy2023-01-287 citations

Plain language summary of the effects of iclepertin (BI 425809) on cognition in patients with schizophrenia

Future Neurology2022-06-30

Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study.

2021-03-0198 citations

Evaluation of the efficacy and safety of orally administered BI425809 during a 12‐week treatment period compared with placebo in patients with cognitive impairment due to Alzheimer’s disease

Alzheimer s & Dementia2020-12-01

Evaluation of the Efficacy of BI 425809 Pharmacotherapy in Patients with Schizophrenia Receiving Computerized Cognitive Training: Methodology for a Double-blind, Randomized, Parallel-group Trial.

2020-04-0118 citations

P1‐062: A PHASE II STUDY EVALUATING EFFICACY, SAFETY, AND TOLERABILITY OF ORAL BI 425809 IN PATIENTS WITH COGNITIVE IMPAIRMENT DUE TO ALZHEIMER'S DISEASE DEMENTIA

Alzheimer s & Dementia2019-07-01

S27. EFFICACY, SAFETY, AND PHARMACOKINETICS OF BI 425809 ONCE DAILY IN PATIENTS WITH SCHIZOPHRENIA: METHODOLOGY OF A RANDOMIZED TRIAL

Schizophrenia Bulletin2019-04-011 citations